
Sol-Gel Technologies (SLGL) Stock Forecast & Price Target
Sol-Gel Technologies (SLGL) Analyst Ratings
Bulls say
Sol-Gel Technologies Ltd has demonstrated a promising financial outlook, highlighted by a significant increase in projected peak annual sales for its products, as the anticipated pricing per patient has risen from $150K to $250K. The company’s lead product candidate, SGT-610, has the potential to generate over $300 million in annual revenue if approved, which positions it positively within the dermatology market, specifically for Gorlin syndrome patients. Additionally, the current valuation assessment does not factor in potential revenue from SGT-610 in high-frequency basal cell carcinoma indications, suggesting further substantial growth opportunities in the future.
Bears say
The negative outlook on Sol-Gel Technologies's stock stems from significant risks tied to its product pipeline, particularly the pivotal trial of SGT-610 for Gorlin syndrome, which may fail to yield positive results and secure U.S. regulatory approval. Furthermore, the discontinuation of the SGT-210 program for Darier disease highlights potential setbacks that could impede overall growth and market confidence. Additionally, the company's recent 1-for-10 reverse stock split raises concerns about possible medium- to long-term dilution risk, further complicating its financial stability and investor sentiment.
This aggregate rating is based on analysts' research of Sol-Gel Technologies and is not a guaranteed prediction by Public.com or investment advice.
Sol-Gel Technologies (SLGL) Analyst Forecast & Price Prediction
Start investing in Sol-Gel Technologies (SLGL)
Order type
Buy in
Order amount
Est. shares
0 shares